Reviva Pharmaceuticals Holdings, Inc.: 10-Q filed 2024-11-14
What Reviva Pharmaceuticals Holdings, Inc. reported in its quarterly report filed 2024-11-14 (fiscal Q3 2024): 28 published measures, 84 facts as tagged in accession 0001437749-24-035375.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2024-11-14
- Fiscal period
- fiscal Q3 2024
- Accession
- 0001437749-24-035375 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Reviva Pharmaceuticals Holdings, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 7,629,872 | USD | |
| At 2023-12-31 | 23,700,388 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 17,611,760 | USD | |
| At 2023-12-31 | 17,981,672 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | -9,981,888 | USD | |
| At 2024-06-30 | -6,041,522 | USD | |
| At 2023-12-31 | 5,718,716 | USD | |
| At 2023-09-30 | -12,810,721 | USD | |
| At 2023-06-30 | -1,815,195 | USD | |
| At 2022-12-31 | 8,394,246 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 5,558,817 | USD | |
| At 2023-12-31 | 23,367,456 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | -8,365,798 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -23,659,325 | USD | 274 |
| 2023-07-01 to 2023-09-30 | -11,345,936 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -29,905,573 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | -24,443,419 | USD | 274 |
| 2023-01-01 to 2023-09-30 | -19,447,908 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | 6,634,780 | USD | 274 |
| 2023-01-01 to 2023-09-30 | 5,900,350 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | -158,013,573 | USD | |
| At 2023-12-31 | -134,354,248 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | 33,804,693 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 31,424,395 | shares | 274 |
| 2023-07-01 to 2023-09-30 | 23,637,367 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 22,655,737 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | -0.25 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | -0.75 | USD/shares | 274 |
| 2023-07-01 to 2023-09-30 | -0.48 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -1.32 | USD/shares | 273 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | 0 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 14,781 | USD | 274 |
| 2023-07-01 to 2023-09-30 | 12,117 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 21,531 | USD | 273 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | 1,076,125 | USD | 274 |
| 2023-01-01 to 2023-09-30 | 3,022,756 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | -8,462,534 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -24,514,283 | USD | 274 |
| 2023-07-01 to 2023-09-30 | -11,563,954 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -29,884,290 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 6,810,151 | USD | |
| At 2023-12-31 | 23,700,388 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 17,533,876 | USD | |
| At 2023-12-31 | 17,175,017 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 8,777,579 | USD | |
| At 2023-12-31 | 3,849,108 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | 8,462,534 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 24,514,283 | USD | 274 |
| 2023-07-01 to 2023-09-30 | 11,563,954 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 29,884,290 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | 6,858,285 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 18,226,497 | USD | 274 |
| 2023-07-01 to 2023-09-30 | 9,572,180 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 23,312,661 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 33,441,199 | shares | |
| At 2023-12-31 | 27,918,560 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 148,028,341 | USD | |
| At 2023-12-31 | 140,070,172 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 325,808 | USD | |
| At 2023-12-31 | 254,637 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | -8,365,798 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -23,644,544 | USD | 274 |
| 2023-07-01 to 2023-09-30 | -11,333,819 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -29,884,042 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | 1,604,249 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 6,287,786 | USD | 274 |
| 2023-07-01 to 2023-09-30 | 1,991,774 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 6,571,629 | USD | 273 |
Nonoperating interest expense
Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | 5,146 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 13,786 | USD | 274 |
| 2023-07-01 to 2023-09-30 | 5,901 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 20,414 | USD | 273 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | -23,687 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -159,202 | USD | 274 |
| 2023-07-01 to 2023-09-30 | 5,194 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -15,220 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | 96,736 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 869,739 | USD | 274 |
| 2023-07-01 to 2023-09-30 | 230,135 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 248 | USD | 273 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | 13,786 | USD | 274 |
| 2023-01-01 to 2023-09-30 | 20,414 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | 4,928,471 | USD | 274 |
| 2023-01-01 to 2023-09-30 | 1,758,104 | USD | 273 |
Inspect the source
- Entity
- Reviva Pharmaceuticals Holdings, Inc. / CIK 0001742927
- Captured
- 2026-09-19T11:20:56.685Z
- SEC response SHA-256
26f740ff1a169faebcba46f28197dc15a1be7bab2feb9b4952e7b7f15df066e6
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001742927.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))